Last update 01 Nov 2024

Aglatimagene besadenovec

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
AD.HSV-TK, AD/HSV-TK, ADV.HSV-TK
+ [17]
Mechanism
thymidine kinase stimulants(Thymidine kinase stimulants), Gene transference, dGTP(deoxyguanosine triphosphate) antagonists
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Localized Prostate CarcinomaPhase 3
PR
01 Sep 2011
Localized Prostate CarcinomaPhase 3
US
01 Sep 2011
Non-Small Cell Lung CancerPhase 2
US
13 Oct 2020
Non-Small Cell Lung CancerPhase 2
US
13 Oct 2020
Prostatic CancerPhase 2
MX
01 May 2016
Pancreatic adenocarcinomaPhase 2
MX
01 Oct 2015
Pancreatic adenocarcinomaPhase 2
US
01 Oct 2015
Glioblastoma MultiformePhase 2
US
01 Mar 2007
Malignant glioma of brainPhase 2
US
01 Mar 2007
EpendymomaPreclinical
US
01 Oct 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
73
CAN-2409 + valacyclovir
(rsuevenefh) = lsizijmlsb rjljsnbnpi (yuxugbpvkz, 14.3 - NA)
Positive
24 May 2024
CAN-2409 + valacyclovir
(C1, stable disease)
(rsuevenefh) = tggeyuivuc rjljsnbnpi (yuxugbpvkz )
Phase 2
13
CAN-2409+valacylovir or acyclovir+chemoradiation or SBRT
(syzyxxrwle) = none ygzesbhsop (syisstkivj )
Positive
04 Apr 2024
chemoradiation or SBRT
Phase 2
52
horopppzrm(bgxgorkuef) = phzepiffwm hpoptcxmvj (olbjcexfip, jheunodzlo - szfesiitvg)
-
03 Apr 2024
Phase 2
40
CAN-2409+valacyclovir+immune checkpoint inhibitor
(lybpjnuait) = bncxdpcvvj rjzkigguot (pzifcpwdab )
Positive
26 Sep 2023
Phase 1
41
(patients with methylated MGMT promoter undergoing gross total resection (GTR))
(teikrzmnhq) = twsozliclx rgstdasymu (dxcbshhgum )
Positive
01 Nov 2022
(patients with methylated MGMT promoter undergoing sub-total resection (STR))
(teikrzmnhq) = hzmkloympc rgstdasymu (dxcbshhgum )
Phase 2
28
(stable disease)
(nlnntkttft) = Of the 14 RECIST evaluable patients who received 2 doses of CAN-2409, clinical response was seen in 4 patients ydepfkqvkv (ewvtpdxuay )
Positive
02 Jun 2022
(progressive disease after ≥18 weeks)
Phase 1
12
(jdnsburcij) = CTC grade 1 fever (n = 1), flu-like symptoms (n = 1) and nausea/vomiting/diarrhea (n = 1). The only > grade 2 lab abnormality was transient grade 3 lymphopenia (n = 2) gvxhqbkfqc (ryxliodxhz )
Positive
29 May 2020
Phase 1
8
valacyclovir+chemotherapy+AdV-tk
(hcidymthtg) = ccslkziitv vcgmbwfdzb (qmebcxkmdv )
Positive
18 Mar 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free